Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACE2-scFc protein therapeutic - United Biomedical

Drug Profile

ACE2-scFc protein therapeutic - United Biomedical

Latest Information Update: 04 Mar 2020

At a glance

  • Originator United Biomedical
  • Class Antivirals; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 26 Feb 2020 United Biomedical files for patent protection for ACE2-scFc protein therapeutic and its manufacturing process
  • 26 Feb 2020 Early research in COVID-2019-infections in Taiwan (Parenteral)

Development Overview

Introduction

An ACE2-scFc protein therapeutic is being developed as an antiviral therapy, for the treatment of COVID-2019 infections by United Biomedical. The company-developed ACE2-scFc protein competitively inhibits the entry of the virus into host cells, wherein the virus binds to it, instead of the ACE2 receptor. The ACE2-scFc protein replaces the neutralising antibody therapy taken from patients recovering from infection and is expected to have better efficacy and longer half-life for patients, relative to that conferred by the antibody. Additionally, the blocking effect of the protein on the virus remains unfazed by viral mutation. Early research is underway in Taiwan.

Patent Information

In February 2020, United Biomedical reported that it has filed patent applications related to its products and associated manufacturing process details based on the biological information related to 2019-nCoV virus and its receptor ACE2 [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antivirals, Proteins
  • Mechanism of Action Undefined mechanism
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research Taiwan Parenteral / unspecified United Biomedical 26 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
United Biomedical Originator USA
United Biomedical Owner USA

Development History

Event Date Update Type Comment
26 Feb 2020 Patent Information United Biomedical files for patent protection for ACE2-scFc protein therapeutic and its manufacturing process [1] Updated 04 Mar 2020
26 Feb 2020 Phase Change Early research in COVID-2019-infections in Taiwan (Parenteral) [1] Updated 04 Mar 2020

References

  1. UBI Group's scientific research energy will tackle the human catastrophe caused by the new crown pneumonia virus.

    Media Release
Back to top